Show simple item record

dc.contributor.authorWeissler, E. H.
dc.contributor.authorNaumann, Tristan
dc.contributor.authorAndersson, Tomas
dc.contributor.authorRanganath, Rajesh
dc.contributor.authorElemento, Olivier
dc.contributor.authorLuo, Yuan
dc.contributor.authorFreitag, Daniel F.
dc.contributor.authorBenoit, James
dc.contributor.authorHughes, Michael C.
dc.contributor.authorKhan, Faisal
dc.contributor.authorSlater, Paul
dc.contributor.authorShameer, Khader
dc.contributor.authorRoe, Matthew
dc.contributor.authorHutchison, Emmette
dc.contributor.authorKollins, Scott H.
dc.contributor.authorBroedl, Uli
dc.date.accessioned2021-11-01T14:33:53Z
dc.date.available2021-11-01T14:33:53Z
dc.date.issued2021-08-16
dc.identifier.urihttps://hdl.handle.net/1721.1/136869
dc.description.abstractAbstract Background Interest in the application of machine learning (ML) to the design, conduct, and analysis of clinical trials has grown, but the evidence base for such applications has not been surveyed. This manuscript reviews the proceedings of a multi-stakeholder conference to discuss the current and future state of ML for clinical research. Key areas of clinical trial methodology in which ML holds particular promise and priority areas for further investigation are presented alongside a narrative review of evidence supporting the use of ML across the clinical trial spectrum. Results Conference attendees included stakeholders, such as biomedical and ML researchers, representatives from the US Food and Drug Administration (FDA), artificial intelligence technology and data analytics companies, non-profit organizations, patient advocacy groups, and pharmaceutical companies. ML contributions to clinical research were highlighted in the pre-trial phase, cohort selection and participant management, and data collection and analysis. A particular focus was paid to the operational and philosophical barriers to ML in clinical research. Peer-reviewed evidence was noted to be lacking in several areas. Conclusions ML holds great promise for improving the efficiency and quality of clinical research, but substantial barriers remain, the surmounting of which will require addressing significant gaps in evidence.en_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofhttps://doi.org/10.1186/s13063-021-05489-xen_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceBioMed Centralen_US
dc.titleThe role of machine learning in clinical research: transforming the future of evidence generationen_US
dc.typeArticleen_US
dc.identifier.citationTrials. 2021 Aug 16;22(1):537en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering & Science
dc.identifier.mitlicensePUBLISHER_CC
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2021-08-22T03:11:03Z
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dspace.date.submission2021-08-22T03:11:03Z
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Needed


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record